Guggenheim initiated coverage of X4 Pharmaceuticals (NasdaqCM: XFOR) with a Buy on March 9, 2026, and a price forecast implying approximately 129.12% upside. Reported by Fintel, the analyst initiation is a bullish signal that may prompt short-term re-rating of the stock; investors should review the underlying clinical and financial catalysts before positioning.
Guggenheim initiated coverage of X4 Pharmaceuticals (NasdaqCM: XFOR) with a Buy on March 9, 2026, and a price forecast implying approximately 129.12% upside. Reported by Fintel, the analyst initiation is a bullish signal that may prompt short-term re-rating of the stock; investors should review the underlying clinical and financial catalysts before positioning.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
